Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & EVP. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendment (CLIA).
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Ossium Health is a privately held bioengineering and biotechnology company developing an organ-donor-derived bone-marrow banking platform. It recovers bone marrow from deceased organ donors, cryopreserves it, and makes hematopoietic stem-cell grafts available on demand for transplantation and other cell-therapy applications.
Primary product
An off-the-shelf, cryopreserved bone-marrow-derived hematopoietic stem-cell product, supported by the PRESERVE I clinical program; the company also offers OssiGraft and OssiGraft Prime viable bone-matrix allografts for orthopedic and spine procedures.
Founded
2016
Headquarters
80 Tehama Street, San Francisco, California 94105, United States
Team size
70-80
Industry
Biotechnology Research
Sub-industry
Cell therapy, hematopoietic stem-cell transplantation, tissue banking, cryopreservation, and regenerative medicine
Offices
Business model
Stage
Series C / clinical-stage biotechnology company
Total raised
$128.9M
Latest round
Series C · Jul 2023
Latest amount
$52M
Jul 2023 · CPMG
Mar 2021 · Vivo Capital and General Catalyst
Jun 2020
May 2018
California Institute for Regenerative Medicine
Leadership
Chief Executive Officer, President, and Co-Founder
Executive Vice President, Chief Science Officer, and Co-Founder
Chief Commercial Officer
Vice President, Research
Director of Technology
Director, Regulatory Affairs
Chip Walker-Wilson
Senior Vice President and General Counsel
Preethi Prasad
Senior Director, Clinical Operations
Founders
Historical founder, former CEO, and former executive chairman; current role at Ossium is not confirmed
Ossium describes itself as mission-driven, results-oriented, data-led, ownership-minded, and resilient. Its work combines regulated manufacturing, clinical research, and biotechnology product development. The company has emphasized its impact on patients, donor families, clinical partners, and the broader transplant ecosystem.
Compensation
Publicly surfaced estimates include approximately $54,199 annually for Cell Therapy Associate II, $76,214 for Quality Engineer, and $100,763 for Quality Manager. These are third-party estimates rather than confirmed company salary bands; public evidence of visa sponsorship is unavailable.
Benefits
Pricing
Not publicly disclosed. The company appears to use institutional, clinical, commercial-product, distribution, and government-contract arrangements rather than consumer subscription pricing.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Approximately $1M-$10M annually; one third-party estimate is $1.2M
Estimated monthly visits
4.5K
Traffic estimate as of Jun 2026
Ossium announced a BARDA contract initially funded at $21 million, with potential value up to $125 million over five years. The contract supports national preparedness but includes option-dependent potential value rather than guaranteed revenue.
SourceIndependent reporting identified important clinical and scaling uncertainties, including possible effects of freezing on cell quality, potential relapse risk, the need for a large and diverse donor pool, and the requirement to demonstrate clinical effectiveness at scale.
SourceCommentary on the early PRESERVE I data noted that the clinical sample remains very small and that longer-term relapse, graft-versus-host disease, durability, product consistency, reimbursement, and regulatory classification remain unresolved questions.
SourceBusiness Wire · Dec 2025
Ossium reported early data from four patients with hematologic malignancies treated with deceased-organ-donor-derived marrow; all four achieved reported neutrophil engraftment, platelet recovery, and full donor chimerism, with no chronic graft-versus-host disease reported by the company.
Ossium Health · Nov 2025
Ossium appointed Susannah Cantrell as chief commercial officer to lead commercial strategy, go-to-market planning, partnerships, and preparation for broader transplant-center availability.
WIRED · Nov 2024
WIRED described Ossium’s deceased-donor marrow-recovery and cryopreservation approach, its early clinical use, partnerships with organ-procurement organizations, and open questions around scale, cell quality, donor diversity, and clinical validation.
Ossium Health · Sep 2024
Ossium announced a BARDA contract initially funded at $21 million, with potential total value of up to $125 million including options over five years.
Ossium Health · Sep 2024
The company reported its first leukemia patient treated with its product achieved neutrophil engraftment by day 16 and platelet engraftment by day 21, with no product-related adverse events reported at that time.
4 jobs at Ossium Health